CTP-543

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Alopecia Areata

Conditions

Alopecia Areata

Trial Timeline

Oct 19, 2021 → Jul 18, 2024

NCT ID

NCT05041803

About CTP-543

CTP-543 is a phase 3 stage product being developed by Sun Pharmaceutical for Alopecia Areata. The current trial status is completed. This product is registered under clinical trial identifier NCT05041803. Target conditions include Alopecia Areata.

What happened to similar drugs?

1 of 19 similar drugs in Alopecia Areata were approved

Approved (1) Terminated (0) Active (18)

🔄Deuruxolitinib + PlaceboSun PharmaceuticalPhase 3

✅Baricitinib 4 MG Oral TabletEli LillyApproved

🔄Baricitinib + PlaceboEli LillyPhase 3

🔄minoxidilJohnson & JohnsonPhase 3

🔄5% Minoxidil + 2% MinoxidilJohnson & JohnsonPhase 3

🔄5% Minoxidil Topical Foam + Vehicle Topical FoamJohnson & JohnsonPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05041803	Phase 3	Completed	Oct 19, 2021	Jul 18, 2024	Alopecia Areata
NCT03898479	Phase 2/3	Active	Apr 4, 2019	Jun 1, 2027	Alopecia Areata

Competing Products

20 competing products in Alopecia Areata

See all competitors

Product	Company	Stage	Hype Score
Baricitinib	Eli Lilly	Phase 2	42
CTP-543	Sun Pharmaceutical	Phase 2/3	42
Deuruxolitinib + Placebo	Sun Pharmaceutical	Phase 3	47
Baricitinib + Placebo	Eli Lilly	Phase 2/3	38
Baricitinib 4 MG Oral Tablet	Eli Lilly	Approved	47
Baricitinib + Placebo	Eli Lilly	Phase 3	47
Baricitinib + Placebo	Eli Lilly	Phase 3	40
minoxidil	Johnson & Johnson	Phase 3	40
5% Minoxidil + 2% Minoxidil	Johnson & Johnson	Phase 3	40
Minoxidil + vehicle of 5% Minoxidil topical foam	Johnson & Johnson	Phase 2	35
5% Minoxidil Topical Foam + Vehicle Topical Foam	Johnson & Johnson	Phase 3	40
Upadacitinib + Upadacitinib Placebo	AbbVie	Phase 3	47
Upadacitinib + Placebo	AbbVie	Phase 3	47
Secukinumab + Placebo	Novartis	Phase 2	27
Daxdilimab	Amgen	Phase 2	35
Ritlecitinib	Pfizer	Pre-clinical	30
LITFULO	Pfizer	Pre-clinical	30
Ritlecitinib	Pfizer	Pre-clinical	33
Ritlecitinib higher dose + Ritlecitinib lower dose + Placebo	Pfizer	Phase 3	47
Ritlecitinib	Pfizer	Pre-clinical	26